Amarin gains 315% after data link triglycerides with CV risk

Amarin Corp. plc. (NASDAQ:AMRN) jumped $9.41 (315%) to $12.40 on Monday after top-line data from the Phase III REDUCE-IT trial showed that once-daily 4 g Vascepa icosapent ethyl led to a 25% reduction in major adverse cardiovascular events (MACE) vs. placebo, meeting the primary endpoint (p<0.001).


Read the full 462 word article

User Sign In